Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer - Report of 2 cases

Onkologie

Volumn 28, Issue 11, 2005, Pages 589-592

  Wolschke, Christine ^a   Goekkurt, Eray ^b   Al Batran, Salah Eddin ^c   Hossfeld, Dieter Kurt ^a   Stoehlmacher, Jan ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c KRANKENHAUS NORDWEST   (Germany)

Author keywords

Chemotherapy; Gastric cancer; Pharmacogenetics

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; LOPERAMIDE; MITOMYCIN C; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SODIUM CHLORIDE;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DNA DETERMINATION; DNA EXTRACTION; DNA REPAIR; DNA SEQUENCE; DRUG EFFECT; DRUG METABOLISM; ENZYME METABOLISM; FEMALE; FOLLOW UP; GASTRECTOMY BILLROTH II; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; PERITONEUM CANCER; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; STOMACH; STOMACH CANCER; STOMACH RADIOGRAPHY; SURVIVAL RATE; SURVIVAL TIME; TOTAL STOMACH RESECTION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 27244458397     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088916     Document Type: Article

References (17)

1. Janunger KG, Hafstrom L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001;40:309-326.
2. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
3. Stoehlmacher J: Pharmacogenetics in gastrointestinal tumors. Onkologie 2005;28:435-440.
4. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001;7:1149-1153.
5. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-354.
6. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004;14:319-327.
7. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003;63:2898-2904.
8. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
9. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229.
10. Marcuello E, Altes A, Del Rio E, Cesar A, Menoyo A, Baiget M: Single nucleotide polymorphism in the 5′ tandem repeat sequenze of thymidylate synthase gene predicts for response to fluorouracil based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004;112:733-737.
11. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12:555-558.
12. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.
13. Tsuchida S and Sato K: Glutathion transferases and cancer. Crit Rev Biochem Mol Biol 1992;27:337-384.
14. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer: J Natl Cancer Inst 2002;94:936-942.
15. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-344.
16. Al-Batran S, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel JM, Seipelt G, Rost A, Orth J, Knuth J, Jaeger E: Phase II trial of bi-weekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658-663.
17. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann E: Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003;(abstr 999).